XML 34 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies (Tables)
 3 Months Ended
Mar. 31, 2017
Commitments and Contingencies [Abstract]  
Summary of milestone payments
Milestones Date Met Payments 
      
(1) when Company initiates a Phase 1 Clinical Trial of a licensed product July 24, 2012 $750,000 
(2) when Company initiates a Phase 2 Clinical Trial of a licensed product September __, 2016  750,000 
(3) when Company initiates a Phase 3 Clinical Trial of a licensed product In future  1,500,000 
(4) Biological License Application filing with U.S. FDA In future  1,750,000 
(5) First commercial sale In future  1,500,000 
(6) after the first $10,000,000 in net sales In future  1,500,000 
Total   $7,750,000 
Schedule of future minimum obligations on the lease
For the year ending December 31, 2018  199,440 
Total $199,440